Patent Assignment
Reel/Frame 073634/0354
Security Interest
Recorded: 2025-11-19
Pages: 86
Assignor
MODERNATX, INC.
Executed: 2025-11-19
Assignee
ARES CAPITAL CORPORATION, AS AGENT
245 PARK AVENUE, 44TH FLOOR, NEW YORK, NEW YORK, 10167
Covered Properties
(410)
Dlin-KC2-Dma Lipid Nanoparticle Delivery of Modified Polynucleotides
Modified Polynucleotides for the Production of G-Csf
Engineered Nucleic Acids and Methods of Use Thereof
Compositions and Methods of Altering Cholesterol Levels
Method for Producing a Protein of Interest in a Primate
Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease
Modified Polynucleotides for Treating Protein Deficiency
Modified Polynucleotides for Treating Galactosylceramidase Protein Deficiency
Modified Polynucleotides Encoding Aryl Hydrocarbon Receptor Nuclear Translocator
Modified Polynucleotides Encoding Copper Metabolism (MURR1) Domain Containing 1
Modified Polynucleotides Encoding CITED4
Split Dose Administration
Modified Polynucleotides Encoding Basic Helix-Loop-Helix Family, Member E41
Modified Polynucleotides for the Production of Secreted Proteins
Modified Polynucleotides Encoding Septin-4
Modified Polynucleotides Encoding Granulysin
Modified Polynucleotides for the Production of Proteins Associated with Blood and Lymphatic Disorders
Engineered Nucleic Acids and Methods of Use Thereof
Modified Polynucleotides for the Production of Proteins
In Vivo Production of Proteins
Modified Polynucleotides Encoding Siah E3 Ubiquitin Protein Ligase 1
Modified Polynucleotides Encoding Aquaporin-5
Formulation and Delivery of Plga Microspheres
Modified Polynucleotides for the Production of Proteins Associated with Blood and Lymphatic Disorders
Modified Polynucleotides for the Production of Nuclear Proteins
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
Modified Polynucleotides Encoding Apoptosis Inducing Factor 1
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
Formulation and Delivery of Plga Microspheres
Engineered Nucleic Acids and Methods of Use Thereof
Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins
Modified Polynucleotides for the Production of Nuclear Proteins
Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins
Delivery and Formulation of Engineered Nucleic Acids
Enzymes and Polymerases for the Synthesis of Rna
Terminally Modified Rna
In Vivo Production of Proteins
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
Modified Polynucleotides for the Production of Proteins Associated with Human Disease
Engineered Nucleic Acids and Methods of Use Thereof
Enzymes and Polymerases for the Synthesis of Rna
Modified Polynucleotides Encoding Hepatitis a Virus Cellular Receptor 2
Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease
Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof
Modified Polynucleotides for the Production of Proteins
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Modified Polynucleotides for the Production of Secreted Proteins
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Nucleic Acid Vaccines
Engineered Nucleic Acids and Methods of Use Thereof
Delivery and Formulation of Engineered Nucleic Acids
Nucleic Acid Vaccines
Polynucleotide Compositions Containing Amino Acids
Combination PIV3/Hmpv Rna Vaccines
Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof
Removal of Dna Fragments in Mrna Production Process
Human Cytomegalovirus Rna Vaccines
Cancer Vaccines
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Methods of Using OX40 Ligand Encoding Polynucleotides
Compounds and Compositions for Intracellular Delivery of Agents
Manufacturing Methods for Production of Rna Transcripts
Compositions and Methods for Delivery of Agents
Terminally Modified Rna
Chikagunya Virus Rna Vaccines
High Potency Immunogenic Compositions
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Formulation and Delivery of Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions
Alternative Nucleic Acid Molecules and Uses Thereof
Combination PIV3/Hmpv Rna Vaccines
Mrna Combination Therapy for the Treatment of Cancer
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Methods of Using OX40 Ligand Encoding Polynucleotides
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Human Cytomegalovirus Rna Vaccines
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Polynucleotide Molecules and Uses Thereof
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
Methods of Using OX40 Ligand Encoding Polynucleotides
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Modified Polynucleotides for the Production of Secreted Proteins
Circular Polynucleotides
Phosphate Replacement Mrna Cap Analogs
Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
In Vitro Transcription Methods and Constructs
Patent:
10,465,190 →
Application:
15/387,263 →
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Rna Cancer Vaccines
Application:
16/482,844 →
Publication:
US US20190351040A1
Compositions and Methods for Delivery of Agents
Zika Rna Vaccines
In Vivo Production of Proteins
Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides
Sexually Transmitted Disease Vaccines
Zika Virus Rna Vaccines
Polynucleotides Encoding Alpha-Galactosidase a for the Treatment of Fabry Disease
Polynucleotides Encoding Alpha-Galactosidase a for the Treatment of Fabry Disease
Rna Polymerase Variants
Hmpv Rna Vaccines
Phosphate Replacement Mrna Cap Analogs
In Vivo Production of Proteins
Compositions and Methods for Delivery of Agents
Ion Exchange Purification of Mrna
Phosphate Replacement Mrna Cap Analogs
Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
High Purity Rna Compositions and Methods for Preparation Thereof
Modified Polynucleotides for the Production of Secreted Proteins
Zika Virus Mrna Vaccines
Nucleic Acid Vaccines
Betacoronavirus Mrna Vaccine
Human Cytomegalovirus Vaccine
Modified Polynucleotides for the Production of Secreted Proteins
Chikv Rna Vaccines
Human Cytomegalovirus Rna Vaccines
Chikungunya Virus Rna Vaccines
Polynucleotides Encoding Relaxin
Compounds and Compositions for Intracellular Delivery of Agents
Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease
Polynucleotides Encoding Immune Modulating Polypeptides
Engineered Nucleic Acids and Methods of Use Thereof
Methods for Therapeutic Administration of Messenger Ribonucleic Acid Drugs
Delivery and Formulation of Engineered Nucleic Acids
Removal of Dna Fragments in Mrna Production Process
Terminally Modified Rna
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Influenza Vaccine
Immunomodulatory Therapeutic Mrna Compositions Encoding Activating Oncogene Mutation Peptides
Betacoronavirus Mrna Vaccine
Polynucleotides Encoding Galactose-1-Phosphate Uridylyltransferase for the Treatment of Galactosemia Type 1
Polynucleotides Encoding Citrin for the Treatment of Citrullinemia Type 2
Methods of Using OX40 Ligand Encoding Polynucleotides
Mrna Combination Therapy for the Treatment of Cancer
Assembly and Error Reduction of Synthetic Genes from Oligonucleotides
Varicella Zoster Virus (Vzv) Vaccine
Branched Tail Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE
Rna Polymerase Variants
Sterol Purification
Application:
17/278,095 →
Publication:
US US20210347810A1
Respiratory Virus Nucleic Acid Vaccines
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Human Cytomegalovirus Vaccine
High Purity Rna Compositions and Methods for Preparation Thereof
Zika Virus Mrna Vaccines
Methods of Preparing Lipid Nanoparticles
Crystal Forms of Amino Lipids
Crystal Forms of Amino Lipids
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Zika Virus Rna Vaccines
Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
Vortex Mixers and Associated Methods, Systems, and Apparatuses Thereof
Hmpv/HPIV3 Mrna Vaccine Composition
Patent:
11,351,242 →
Application:
16/788,182 →
Rna Cancer Vaccines
Application:
17/291,947 →
Publication:
US US20220125899A1
Fed-Batch in Vitro Transcription Process
Heterologous UTR Sequences for Enhanced mRNA Expression
Methods of Using OX40 Ligand Encoding Polynucleotides
Polynucleotides Encoding Branched-Chain Alpha-Ketoacid Dehydrogenase Complex E1-Alpha, E1-Beta, and E2 Subunits for the Treatment of Maple Syrup Urine Disease
Expanded T Cell Assay
Application:
17/615,202 →
Publication:
US US20220236253A1
Human Cytomegalovirus Vaccine
Polynucleotides Encoding Tethered Interleukin-12 (IL12) Polypeptides and Uses Thereof
Modified Polynucleotides for the Production of Membrane Proteins
Application:
16/860,121 →
Publication:
US US20220273555A1
Polynucleotides Containing a Morpholino Linker
Compositions and Methods for Delivery of Agents
Compositions and Methods for Delivery of Rna Interference Agents to Immune Cells
Application:
17/631,216 →
Publication:
US US20220280639A1
Human Cytomegalovirus Rna Vaccines
Respiratory Syncytial Virus Vaccine
Rna Polymerase Variants for Co-Transcriptional Capping
Compositions and Methods for Delivery of Nucleic Acids
Application:
17/276,983 →
Publication:
US US20220298516A1
Modified Messenger Rna Comprising Functional Rna Elements
Lnp-Formulated Mrna Therapeutics and Use Thereof for Treating Human Subjects
Application:
17/641,469 →
Publication:
US US20220323482A1
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
Cap Guides and Methods of Use Thereof for Rna Mapping
Application:
17/761,420 →
Publication:
US US20220349006A1
Stabilized Formulations
Processes for Purifying Downstream Products of in Vitro Transcription
Application:
17/634,939 →
Publication:
US US20220348900A1
Lipid Nanoparticle Compositions and Methods of Formulating the Same
Zoonotic Disease Rna Vaccines
Sterol Analogs and Uses Thereof
Application:
17/277,829 →
Publication:
US US20220402965A1
Carbonate Containing Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Novel Headgroup Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Application:
17/761,863 →
Publication:
US US20230000773A1
Methods for Preparing Particles and Related Compositions
Human Cytomegalovirus Vaccine
Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins
Methods for Therapeutic Administration of Messenger Ribonucleic Acid Drugs
Broad Spectrum Influenza Virus Vaccine
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
Branched Tail Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Stabilized Formulations of Lipid Nanoparticles
Long-Lived Polynucleotide Molecules
Nucleic Acid Vaccines for Varicella Zoster Virus (Vzv)
Patent:
11,643,441 →
Application:
15/767,587 →
Methods of Making Tolerogenic Dendritic Cells
Application:
17/758,520 →
Publication:
US US20230112857A1
Rna Formulations for High Volume Distribution
Application:
17/925,114 →
Publication:
US US20230142529A1
Lipid Nanoparticle Compositions and Methods of Formulating the Same
Mrnas Encoding Metabolic Reprogramming Polypeptides and Uses Thereof
Application:
17/759,687 →
Publication:
US US20230130155A1
Mrna Combination Therapy for the Treatment of Cancer
Rna Formulations for High Volume Distribution, and Methods of Using the Same for Treating Covid-19
Application:
17/925,125 →
Publication:
US US20230181481A1
Methylene Blue Stabilized Mrna Compositions
Application:
17/926,353 →
Publication:
US US20230190761A1
Lnp Compositions Comprising an Mrna Therapeutic and an Effector Molecule
Application:
17/924,456 →
Publication:
US US20230173104A1
Methods of Using OX40 Ligand Encoding Polynucleotides
Lipid Nanoparticles for Delivering Modified Rna Encoding a Vegf-a Polypeptide
Signal-Sensor Polynucleotides for the Alteration of Cellular Phenotypes
Use of Mrnas Encoding OX40L, Il-23 and Il-36GAMMA for Treating Cancer
Application:
17/927,940 →
Publication:
US US20230233474A1
Influenza Vaccine
Lipid Nanoparticles Containing Polynucleotides Encoding Glucose-6-Phosphatase and Uses Thereof
Application:
17/928,684 →
Publication:
US US20230233475A1
Polynucleotide Secondary Structure
Application:
18/093,119 →
Publication:
US US20230250439A1
Methods for Preparing Particles and Related Compositions
Application:
18/161,857 →
Publication:
US US20230241002A1
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
Application:
17/989,941 →
Publication:
US US20230270685A1
Phenylalanine Hydroxylase Variants and Uses Thereof
Application:
17/928,680 →
Publication:
US US20230235298A1
Methods of Making Lipid Nanoparticles
Compositions for the Delivery of Payload Molecules to Airway Epithelium
Application:
18/040,485 →
Publication:
US US20230285310A1
Herpes Simplex Virus Vaccine
Bacterial Strains for Dna Production
Application:
18/008,139 →
Publication:
US US20230287437A1
Rna Polymerase Variants
Methods of Preparing Lipid Nanoparticles
Application:
17/792,554 →
Publication:
US US20230285297A1
Polynucleotides Encoding Anti-Chikungunya Virus Antibodies
Sars-Cov-2 Mrna Domain Vaccines
Application:
17/797,784 →
Publication:
US US20230346914A1
Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis
Mrna Combination Therapy for the Treatment of Cancer
Application:
18/190,453 →
Publication:
US US20230346928A1
Respiratory Virus Immunizing Compositions
Application:
17/796,401 →
Publication:
US US20230338506A1
Multi-Proline-Substituted Coronavirus Spike Protein Vaccines
Application:
18/028,126 →
Publication:
US US20230355743A1
Ribonucleic Acid Purification
Respiratory Syncytial Virus Vaccine
Application:
18/314,980 →
Publication:
US US20230390379A1
Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis
Application:
18/036,560 →
Publication:
US US20230406895A1
Methods of Using OX40 Ligand Encoding Polynucleotides
Application:
18/324,724 →
Publication:
US US20230359371A1
Quantitative Cellular Method for Determining the Biological Activity of an Anti-CD26 Ligand
Modified Rna Encoding Vegf-a Polypeptides, Formulations, and Uses Relating Thereto
Combination Hmpv/Rsv Rna Vaccines
Polynucleotides Encoding Ornithine Transcarbamylase for the Treatment of Urea Cycle Disorders
Polynucleotides Encoding Tethered Interleukin-12 (IL12) Polypeptides and Uses Thereof
Analytical Hplc Methods
Lipid Nanoparticle Compositions and Methods of Formulating the Same
Polynucleotides Encoding Propionyl-Coa Carboxylase Alpha and Beta Subunits for the Treatment of Propionic Acidemia
Ribonucleic Acid Purification
Application:
18/036,992 →
Publication:
US US20240025935A1
Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
Application:
18/164,796 →
Publication:
US US20240024422A1
Delivery and Formulation of Engineered Nucleic Acids
Reduction or Elimination of Immune Responses to Non-Intravenous, E.G., Subcutaneously Administered Therapeutic Proteins
Methods for Hplc Analysis
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
Varicella Zoster Virus (Vzv) Vaccine
Rsv Rna Vaccines
Polynucleotides Encoding Phenylalanine Hydroxylase for the Treatment of Phenylketonuria
Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins
Application:
18/161,598 →
Publication:
US US20240131193A1
Variant Strain-Based Coronavirus Vaccines
Application:
18/272,512 →
Publication:
US US20240100151A1
Lipid Nanoparticle Formulation
Vlp Enteroviral Vaccines
Application:
18/280,362 →
Publication:
US US20240100145A1
Variant Strain-Based Coronavirus Vaccines
Application:
18/272,496 →
Publication:
US US20240139309A1
Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions
Application:
18/177,455 →
Publication:
US US20240123035A1
PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS
Application:
18/284,177 →
Publication:
US US20240175005A1
Heterologous UTR Sequences for Enhanced mRNA Expression
Pertussis Vaccine
Application:
18/552,346 →
Publication:
US US20240181030A1
Modified Nucleic Acid Molecules and Uses Thereof
Application:
18/058,656 →
Publication:
US US20240165267A1
Lipid Nanoparticles Containing Polynucleotides Encoding Glucose-6-Phosphatase and Uses Thereof
Application:
18/282,643 →
Publication:
US US20240207374A1
Lipid Nanoparticles and Polynucleotides Encoding Ornithine Transcarbamylase for the Treatment of Ornithine Transcarbamylase Deficiency
Application:
18/282,647 →
Publication:
US US20240189449A1
Epstein-Barr Virus Mrna Vaccines
Application:
18/286,705 →
Publication:
US US20240207392A1
Lipid Nanoparticles Containing Polynucleotides Encoding Phenylalanine Hydroxylase and Uses Thereof
Application:
18/282,639 →
Publication:
US US20240207444A1
Terminally Modified Rna
Lipid Nanoparticles Containing Polynucleotides Encoding Propionyl-Coa Carboxylase Alpha and Beta Subunits and Uses Thereof
Application:
18/282,640 →
Publication:
US US20240216288A1
Mucosal Expression of Antibody Structures and Isotypes by Mrna
Application:
18/284,919 →
Publication:
US US20240209068A1
Respiratory Virus Combination Vaccines
Application:
18/555,087 →
Publication:
US US20240216500A1
Polynucleotides Encoding Methylmalonyl-Coa Mutase for the Treatment of Methylmalonic Acidemia
Application:
18/282,676 →
Publication:
US US20240226025A1
Branched Tail Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Application:
18/551,704 →
Publication:
US US20240226026A1
Alternative Rna Purification Strategies
Application:
18/570,927 →
Publication:
US US20240218353A1
Lyophilization Methods for Preparing Lipid Formulated Therapeutics
Application:
18/288,328 →
Publication:
US US20240226028A1
Methods for Identification and Ratio Determination of Rna Species in Multivalent Rna Compositions
Application:
18/284,938 →
Publication:
US US20240229109A1
Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis
Application:
18/471,617 →
Publication:
US US20240238210A1
Influenza-Coronavirus Combination Vaccines
Application:
18/555,130 →
Publication:
US US20240226277A1
Isoquinoline-Stabilized Lipid Nanoparticle Formulations
Application:
18/556,221 →
Publication:
US US20240238211A1
Delivery and Formulation of Engineered Nucleic Acids
Application:
18/417,715 →
Publication:
US US20240252645A1
Non-Viral Delivery of Dna for Prolonged Polypeptide Expression in Vivo
Application:
18/289,688 →
Publication:
US US20240263195A1
USE OF MRNAS ENCODING OX40L, IL-23 AND IL-36gamma IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE FOR TREATING PARTICULAR CANCERS
Compounds and Compositions for Intracellular Delivery of Agents
Hiv Rna Vaccines
Coronavirus Glycosylation Variant Vaccines
Application:
18/569,776 →
Publication:
US US20240293534A1
Polynucleotides Encoding Methylmalonyl-Coa Mutase for the Treatment of Methylmalonic Acidemia
Application:
18/560,498 →
Publication:
US US20240269248A1
Therapeutic Use of Sars-Cov-2 Mrna Domain Vaccines
Application:
18/282,097 →
Publication:
US US20240299531A1
Polynucleotides Containing a Morpholino Linker
Preparation of Lipid Nanoparticles and Methods of Administration Thereof
Polynucleotides Encoding Relaxin
Modified Polynucleotides for the Production of Proteins Associated with Human Disease
Application:
18/634,220 →
Publication:
US US20240327476A1
Polynucleotides Encoding Propionyl-Coa Carboxylase Alpha and Beta Subunits for the Treatment of Propionic Acidemia
Application:
18/578,052 →
Publication:
US US20240316165A1
Polynucleotides Containing a Stabilizing Tail Region
Processes for Preparing Lipid Nanoparticle Compositions
Application:
18/291,707 →
Publication:
US US20240335393A1
Polynucleotides Encoding JAGGED1 for the Treatment of Alagille Syndrome
Pan-Human Coronavirus Domain Vaccines
Application:
18/577,571 →
Publication:
US US20240358819A1
Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia
Processes for Preparing Lipid Nanoparticle Compositions for the Delivery of Payload Molecules to Airway Epithelium
Application:
18/291,710 →
Publication:
US US20240366522A1
Polynucleotides Encoding Uridine Diphosphate Glycosyltransferase 1 Family, Polypeptide A1 for the Treatment of Crigler-Najjar Syndrome
Application:
18/572,490 →
Publication:
US US20240376445A1
Betacoronavirus Rna Vaccines
Stabilized Formulations of Lipid Nanoparticles
Tropical Disease Vaccines
Application:
18/635,203 →
Publication:
US US20240366745A1
Pan-Human Coronavirus Vaccines
Application:
18/577,563 →
Publication:
US US20240382581A1
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Concatemeric Peptide Epitope Rnas
Modified Polynucleotides for the Production of Secreted Proteins
Application:
18/543,930 →
Publication:
US US20240409597A1
Engineered Polynucleotides for Cell-Type or Microenvironment-Specific Expression
Application:
18/569,888 →
Publication:
US US20240384277A1
Rna Polymerase Variants for Co-Transcriptional Capping
Polynucleotides Encoding Integrin Beta-6 and Methods of Use Thereof
Application:
18/706,652 →
Publication:
US US20250041393A1
Rna Polymerase Variants
Varicella Zoster Virus (Vzv) Vaccine
Markerless Dna Production
Application:
18/702,284 →
Publication:
US US20250011798A1
Compositions for the Delivery of Payload Molecules to Airway Epithelium
Application:
18/709,314 →
Publication:
US US20250049727A1
Processes for Preparing Lipid Nanoparticles
Application:
18/720,092 →
Publication:
US US20250049728A1
Surgery Assisting Device
Application:
18/754,325 →
Publication:
US US20240341884A1
Polynucleotides Encoding Citrin for the Treatment of Citrullinemia Type 2
High Purity Rna Compositions and Methods for Preparation Thereof
Modified Messenger Rna Comprising Functional Rna Elements
Custom Bacterial Strain for Recombinant Protein Production
Application:
18/702,280 →
Publication:
US US20250051736A1
Hiv Rna Vaccines
Application:
18/771,978 →
Publication:
US US20250073327A1
Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides
Application:
18/592,122 →
Publication:
US US20250074962A1
Methods for Therapeutic Administration of Messenger Ribonucleic Acid Drugs
Human Cytomegalovirus Rna Vaccines
Application:
18/812,841 →
Publication:
US US20250082748A1
High Purity Rna Compositions and Methods for Preparation Thereof
Methods of Purifying Dna for Gene Synthesis
Application:
18/725,999 →
Publication:
US US20250084397A1
Delivery and Formulation of Engineered Nucleic Acids
Polynucleotides Encoding Galactose-1-Phosphate Uridylyltransferase for the Treatment of Galactosemia Type 1
Polynucleotides Encoding Glucose-6-Phosphatase for the Treatment of Glycogen Storage Disease Type 1A (GSD1A)
Application:
18/292,058 →
Publication:
US US20250090684A1
In Vitro Transcription Dna Purification and Recycling
Application:
18/728,664 →
Publication:
US US20250115897A1
Respiratory Syncytial Virus Vaccine
Application:
18/796,754 →
Publication:
US US20250099569A1
Nucleic Acid Vaccines
Extraction-Less Reverse Phase (Rp) Chromatography of Mrna Encapsulated in Lipid Nanoparticles for Mrna Purity Assessment
Application:
18/294,279 →
Publication:
US US20250092440A1
BETACORONAVIRUS mRNA VACCINES
Compounds and Compositions for Delivery of Therapeutic Agents
Application:
18/716,220 →
Publication:
US US20250144036A1
Concatemeric Peptide Epitope Rnas
Application:
18/946,487 →
Publication:
US US20250135010A1
Peg Lipids and Uses Thereof
Application:
18/919,839 →
Publication:
US US20250152518A1
Rna Cancer Vaccines
Application:
18/807,315 →
Publication:
US US20250134978A1
COMPOSITIONS AND METHODS FOR DETECTING dsRNA
Application:
19/033,264 →
Publication:
US US20250163187A1
Continuous Precipitation for Mrna Purification
Application:
18/835,106 →
Publication:
US US20250136970A1
Rna Polymerase Variants for Co-Transcriptional Capping
Application:
18/930,766 →
Publication:
US US20250171751A1
Polynucleotides Encoding Glucose-6-Phosphatase for the Treatment of Glycogen Storage Disease
Application:
18/964,899 →
Publication:
US US20250170070A1
Influenza Vaccine
Branched Tail Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Nucleic Acid Vaccines
Nucleic Acid Vaccines for Varicella Zoster Virus (Vzv)
Application:
18/927,762 →
Publication:
US US20250188132A1
Rna Polymerase Variants
Application:
18/955,683 →
Publication:
US US20250197908A1
Polynucleotides Containing a Stabilizing Tail Region
Application:
18/901,649 →
Publication:
US US20250186624A1
Mrnas Encoding Checkpoint Cancer Vaccines and Uses Thereof
Application:
18/839,326 →
Publication:
US US20250213664A1
Cross Mixers for Lipid Nanoparticle Production, and Methods of Operating the Same
Application:
18/851,121 →
Publication:
US US20250214046A1
Methods of Making Lipid Nanoparticles
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
Polynucleotides Encoding Fanconi Anemia, Complementation Group Proteins for the Treatment of Fanconi Anemia
Application:
18/850,319 →
Publication:
US US20250221931A1
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Application:
18/985,208 →
Publication:
US US20250228777A1
Polynucleotides Encoding Porphobilinogen Deaminase for the Treatment of Acute Intermittent Porphyria
Detection of Mrna Purity in a Mixture
Application:
18/855,999 →
Publication:
US US20250250614A1
Methods and Apparatus for Filtration
Rna Polymerase Variants
Application:
18/856,588 →
Publication:
US US20250250551A1
Compounds and Compositions for Intracellular Delivery of Agents
Ribosomal Engagement Potency Assay
Application:
18/856,118 →
Publication:
US US20250251391A1
Betacoronavirus Mrna Vaccines
BETACORONA VIRUS mRNA VACCINES
Delivery and Formulation of Engineered Nucleic Acids
High Purity Rna Compositions and Methods for Preparation Thereof
Application:
19/057,378 →
Publication:
US US20250275999A1
BETACORONAVIRUS mRNA VACCINES
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Lipid Nanoparticle Formulations and Methods of Synthesis Thereof
Application:
18/682,685 →
Publication:
US US20250281418A1
Influenza Vaccine
Lipid Amines
Application:
18/705,140 →
Publication:
US US20250281419A1
Delivery and Formulation of Engineered Nucleic Acids
Messenger Ribonucleic Acids with Extended Half-Life
Application:
18/849,675 →
Publication:
US US20250313830A1
Composition of Mrna-Encoded IL15 Fusion Proteins and Methods of Use Thereof
Application:
18/700,981 →
Publication:
US US20250281583A1
Rsv Rna Vaccines
Methods of Monitoring in Vitro Transcription of Mrna and/or Post-in Vitro Transcription Processes
Mass Spectrometry of Mrna
Application:
18/706,043 →
Publication:
US US20250362278A1
Engineered Polynucleotides for Temporal Control of Expression
Application:
18/998,310 →
Publication:
US US20260035707A1
Small Nuclear Ribonucleoprotein 13 Polypeptides, Polynucleotides, and Uses Thereof
Application:
19/140,087 →
Publication:
US US20260209289A1
Hepatitis B Virus Mrna Vaccines
Application:
63/770,489 →
GPC3-Specific Antibodies, Binding Domains, and Related Proteins and Uses Thereof
Application:
19/133,791 →
Publication:
US US20260191905A1
Herpes Simplex Virus Mrna Vaccines
Application:
18/717,792 →
Publication:
US US20250360194A1
Epstein-Barr Virus Vaccines
Application:
19/084,092 →
Publication:
US US20250312442A1
High-Purity Peg Lipids and Uses Thereof
Mucosal Administration Methods and Formulations
Application:
18/836,530 →
Publication:
US US20250235531A1
Delivery and Formulation of Engineered Nucleic Acids
Drug Product Surrogate Solutions
Application:
18/703,189 →
Publication:
US US20250231165A1
Human Cytomegalovirus Vaccine
Application:
18/926,517 →
Publication:
US US20250228932A1
Seasonal Rna Influenza Virus Vaccines
Terminally Modified Rna
Application:
18/672,502 →
Publication:
US US20250170228A1
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Determination of Encapsulation Efficiency of Lipid Nanoparticles
Application:
18/719,476 →
Publication:
US US20250067729A1
Betacoronavirus Rna Vaccines
Peg Lipids and Uses Thereof
Multicolumn Chromatography Mrna Purification
Application:
18/683,285 →
Publication:
US US20240368580A1
Lipid Nanoparticle Compositions and Methods of Formulating the Same
Application:
18/277,346 →
Publication:
US US20240189242A1
Lnp Compositions Comprising Payloads for in Vivo Therapy
Application:
18/546,145 →
Publication:
US US20240148794A1
High Fidelity in Vitro Transcription
Patent:
11,851,694 →
Application:
16/794,318 →
Nucleic Acid-Based Therapy of Muscular Dystrophies
Application:
18/322,744 →
Publication:
US US20230398074A1
Methods of Preparing Lipid Nanoparticles
Application:
18/040,745 →
Publication:
US US20230277457A1
Lnp Compositions Comprising Mrna Therapeutics with Extended Half-Life
Application:
18/012,094 →
Publication:
US US20230242908A1
Polynucleotides Encoding Alpha-Galactosidase a for the Treatment of Fabry Disease
Rna Affinity Purification
Ribonucleic Acid Purification
Chikv Rna Vaccines
Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof
Patent:
11,344,504 →
Application:
17/352,904 →
Compositions and Methods for Delivery of Agents
Chikungunya Virus Rna Vaccines
Personalized Cancer Vaccine Epitope Selection
Application:
17/255,949 →
Publication:
US US20210268086A1
Infectious Disease Vaccines
Methods and Apparatus for Purifying Rna
Application:
16/311,442 →
Publication:
US US20200308569A1
HPIV3 Rna Vaccines
Modified mRNA Encoding a Propionyl-CoA Carboxylase and Uses Thereof
Application:
16/631,607 →
Publication:
US US20200165593A1
Modified Polynucleotides
Polynucleotides Encoding Low Density Lipoprotein Receptor
Zika Virus Rna Vaccines
Polynucleotides Encoding Immune Modulating Polypeptides
Engineered Nucleic Acids and Methods of Use Thereof
Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides
Engineered Nucleic Acids Encoding a Modified Erythropoietin and Their Expression
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 20, 2013
From: DE FOUGEROLLES, ANTONIN; WOOD, KRISTY M.; ELBASHIR, SAYDA M.
To: MODERNA THERAPEUTICS
Reel/Frame 030653/0085 →
Assignment of Assignor's Interest
Jun 21, 2013
From: SCHRUM, JASON P.
To: MODERNA THERAPEUTICS
Reel/Frame 030656/0800 →
Assignment of Assignor's Interest
Feb 6, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032161/0561 →
Assignment of Assignor's Interest
Feb 6, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032156/0276 →
Assignment of Assignor's Interest
Mar 3, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032338/0313 →
Assignment of Assignor's Interest
Mar 3, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032338/0006 →
Assignment of Assignor's Interest
Mar 3, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032335/0007 →
Assignment of Assignor's Interest
Mar 3, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032339/0553 →
Assignment of Assignor's Interest
Mar 3, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032338/0805 →
Assignment of Assignor's Interest
Mar 3, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032339/0488 →
Assignment of Assignor's Interest
Mar 21, 2014
From: HOGE, STEPHEN G.; DE FOUGEROLLES, ANTONIN; ELLSWORTH, JEFF LYNN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032492/0709 →
Assignment of Assignor's Interest
Sep 30, 2014
From: EJEBE, KENECHI, DR.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 033848/0044 →
Assignment of Assignor's Interest
Sep 30, 2014
From: EJEBE, KENECHI, DR.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 033848/0218 →
Assignment of Assignor's Interest
Sep 30, 2014
From: EJEBE, KENECHI, DR.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 033847/0165 →
Assignment of Assignor's Interest
Sep 30, 2014
From: EJEBE, KENECHI, DR.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 033847/0802 →
Corrective Assignment to Correct the Receiving Party Name Previously Recorded at Reel: 030187 Frame: 0748. Assignor(S) Hereby Confirms the Assignment.
Dec 18, 2014
From: BANCEL, STEPHANE
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034679/0346 →
Corrective Assignment to Correct the Receiving Party Name from Moderna Therapeutics to Moderna Therapeutics, Inc. Previously Recorded on Reel 030653 Frame 0085. Assignor(S) Hereby Confirms the Receiving Party Name on the Attached Patent Assignment Cover Sheet Is Incomplete.
Dec 19, 2014
From: DE FOUGEROLLES, ANTONIN; WOOD, KRISTY M.; ELBASHIR, SAYDA M.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034687/0095 →
Corrective Assignment to Correct the Receiving Party's Name Previously Recorded at Reel: 030656 Frame: 0800. Assignor(S) Hereby Confirms the Assignment.
Dec 19, 2014
From: SCHRUM, JASON P.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034678/0914 →
Corrective Assignment to Correct the Receiving Party's Name Previously Recorded at Reel: 030026 Frame: 0313. Assignor(S) Hereby Confirms the Assignment.
Dec 19, 2014
From: SCHRUM, JASON P.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034678/0847 →
Corrective Assignment to Correct the Receiving Party Name from Moderna Therapeutics to Moderna Therapeutics, Inc. Previously Recorded at Reel: 030041 Frame: 0880. Assignor(S) Hereby Confirms the Assignment.
Dec 19, 2014
From: CHAKRABORTY, TIRTHA; FOUGEROLLES, ANTONIN DE; ELBASHIR, SAYDA M.; JOHN, MATTHIAS
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034686/0074 →
Corrective Assignment to Correct the Receiving Party Name from Moderna Therapeutics to Moderna Therapeutics, Inc. Previously Recorded on Reel 030652 Frame 0727. Assignor(S) Hereby Confirms the Receiving Party Name on the Attached Patent Assignment Cover Sheet Is Incomplete.
Dec 19, 2014
From: DE FOUGEROLLES, ANTONIN; ELBASHIR, SAYDA E.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034687/0059 →
Corrective Assignment to Correct the Receiving Party Name from Moderna Therapeutics to Moderna Therapeutics, Inc. Previously Recorded on Reel 030653 Frame 0010. Assignor(S) Hereby Confirms the Receiving Party Name on the Attached Patent Assignment Cover Sheet Is Incomplete.
Dec 19, 2014
From: DE FOUGEROLLES, ANTONIN; WOOD, KRISTY M.; ELBASHIR, SAYDA E.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034687/0084 →
Corrective Assignment to Correct the Receiving Party Name from Moderna Therapeutics to Moderna Therapeutics, Inc. Previously Recorded on Reel 030631 Frame 0193. Assignor(S) Hereby Confirms the Receiving Party Name on the Attached Patent Assignment Cover Sheet Is Incomplete.
Dec 19, 2014
From: DE FOUGEROLLES, ANTONIN; WOOD, KRISTY M.; ELBASHIR, SAYDA M.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034688/0194 →
Corrective Assignment to Correct the Receiving Party Name and Address Previously Recorded at Reel: 030041 Frame: 0388. Assignor(S) Hereby Confirms the Assignment.
Dec 19, 2014
From: CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; ELBASHIR, SAYDA E.; JOHN, MATTHIAS
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034839/0703 →
Corrective Assignment to Correct the Inventor Name Previously Recorded on Reel 034686 Frame 0074. Assignor(S) Hereby Confirms the Inventor Name in the Previous Cover Sheet Had a Typo.
Jan 15, 2015
From: CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; ELBASHIR, SAYDA M.; JOHN, MATTHIAS
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 034767/0272 →